JP2015180198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015180198A5 JP2015180198A5 JP2015044097A JP2015044097A JP2015180198A5 JP 2015180198 A5 JP2015180198 A5 JP 2015180198A5 JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015180198 A5 JP2015180198 A5 JP 2015180198A5
- Authority
- JP
- Japan
- Prior art keywords
- serine
- serine racemase
- barrier function
- expression level
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100019820 SRR Human genes 0.000 claims 15
- 108010006152 serine racemase Proteins 0.000 claims 15
- 230000000694 effects Effects 0.000 claims 9
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 6
- 230000004625 regulation of water loss via skin Effects 0.000 claims 6
- 210000002510 Keratinocytes Anatomy 0.000 claims 5
- 210000003491 Skin Anatomy 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 3
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- 241000283074 Equus asinus Species 0.000 claims 2
- 108020004999 Messenger RNA Proteins 0.000 claims 2
- 229960001327 Pyridoxal Phosphate Drugs 0.000 claims 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims 2
- 230000004888 barrier function Effects 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 229920002106 messenger RNA Polymers 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- -1 vitamin B 6 compound Chemical class 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015044097A JP6854073B2 (ja) | 2014-03-05 | 2015-03-05 | 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 |
| JP2019186327A JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014043073 | 2014-03-05 | ||
| JP2014043073 | 2014-03-05 | ||
| JP2015044097A JP6854073B2 (ja) | 2014-03-05 | 2015-03-05 | 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186327A Division JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015180198A JP2015180198A (ja) | 2015-10-15 |
| JP2015180198A5 true JP2015180198A5 (ru) | 2016-04-28 |
| JP6854073B2 JP6854073B2 (ja) | 2021-04-07 |
Family
ID=54328827
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015044097A Active JP6854073B2 (ja) | 2014-03-05 | 2015-03-05 | 表皮セリンラセマーゼ及び／又はｄ−セリン量を指標とした、皮膚のバリア機能亢進薬剤のスクリーニング方法並びに皮膚バリア機能評価方法 |
| JP2019186327A Active JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186327A Active JP6934925B2 (ja) | 2014-03-05 | 2019-10-09 | セリンラセマーゼ活性化剤、及び皮膚のバリア機能亢進剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6854073B2 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7172984B2 (ja) * | 2017-03-24 | 2022-11-16 | 味の素株式会社 | 角層機能改善剤 |
| WO2020045364A1 (ja) * | 2018-08-27 | 2020-03-05 | 株式会社 資生堂 | 乾癬を判定するための皮膚試料の分析方法及びシステム |
| JP7237689B2 (ja) * | 2019-03-28 | 2023-03-13 | 株式会社ナリス化粧品 | ストレスに起因する皮膚バリア機能改善剤のスクリーニング方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012008146A2 (pt) * | 2009-09-14 | 2019-09-24 | Shiseido Co Ltd | composição para alívio dos danos causados por meio da irradiação ultravioleta |
-
2015
- 2015-03-05 JP JP2015044097A patent/JP6854073B2/ja active Active
-
2019
- 2019-10-09 JP JP2019186327A patent/JP6934925B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018550037A1 (en) | Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof | |
| Cappellari et al. | “The Social Network” and muscular dystrophies: the lesson learnt about the niche environment as a target for therapeutic strategies | |
| MX366369B (es) | Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo. | |
| JP2015180198A5 (ru) | ||
| Mindaye et al. | Impact of influenza A virus infection on the proteomes of human bronchoepithelial cells from different donors | |
| JP2015511721A5 (ru) | ||
| RU2017122187A (ru) | Клеточный способ определения эффективности дефибротида | |
| Olsen | The oral microbiome in health and disease | |
| JP2004527244A5 (ru) | ||
| MY196578A (en) | Method for Determining Stage of Periodontal Disease | |
| DE602005008710D1 (de) | Verfahren zur untersuchung der aktivität von ionenkanälen | |
| Ilić et al. | Syphacia obvelata modifies mitogen-activated protein kinases and nitric oxide synthases expression in murine bone marrow cells | |
| Samarelli et al. | Small molecules for the treatment of long-COVID-related vascular damage and abnormal blood clotting: a patent-based appraisal | |
| AR097591A1 (es) | Métodos para determinar la respuesta a la terapia | |
| RU2012141281A (ru) | Способ лабораторной оценки эффективности антибактериальной терапии | |
| RU2017139718A (ru) | Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток | |
| JP2016520563A5 (ru) | ||
| AR102509A1 (es) | Kit de prueba para determinar la actividad de una solución que contiene cuat | |
| JP2014028787A5 (ru) | ||
| Wagner et al. | Yersinia pestis and the three plague pandemics–Authors' reply | |
| Hagihara et al. | An experimental study about survey response rate Basic study of efficient strategies to raise the participation rate of Mobility Management | |
| Chastel | Emergence of new viruses in Asia: is climate change involved? | |
| RU2015120411A (ru) | Способ оценки обсемененности пародонта патогенными бактериями с применением полимеразной цепной реакции в реальном времени | |
| WO2013070849A1 (en) | Screening methods for ocular irritation and toxicity | |
| JP2013242298A5 (ru) |